AG
ANIP icon

Aperio Group’s ANI Pharmaceuticals ANIP Stock Holding History

Aperio Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,659
Closed -$312K – 2339
2020
Q1 		$312K Buy
7,659
+1,049
+16% +$55.8K ﹤0.01% 1882
2019
Q4 		$407K Sell
6,610
-211
-3% -$14K ﹤0.01% 1919
2019
Q3 		$497K Sell
6,821
-199
-3% -$14.9K ﹤0.01% 1762
2019
Q2 		$577K Buy
7,020
+664
+10% +$47.2K ﹤0.01% 1698
2019
Q1 		$449K Sell
6,356
-51
-0.8% -$3K ﹤0.01% 1807
2018
Q4 		$288K Buy
6,407
+1,000
+18% +$52.4K ﹤0.01% 1969
2018
Q3 		$306K Sell
5,407
-392
-7% -$24K ﹤0.01% 2001
2018
Q2 		$387K Buy
5,799
+1,019
+21% +$63.6K ﹤0.01% 1876
2018
Q1 		$278K Buy
4,780
+914
+24% +$58K ﹤0.01% 1986
2017
Q4 		$249K Buy
+3,866
New +$241K ﹤0.01% 2049
2017
Q1 		– Sell
-3,349
Closed -$203K – 2143
2016
Q4 		$203K Buy
3,349
+278
+9% +$17K ﹤0.01% 1999
2016
Q3 		$204K Buy
+3,071
New +$192K ﹤0.01% 1926

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Aperio Group's ANIP Position: Q2 2020 in Review

Aperio Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2020, closing a stake of 7,659 shares — an estimated $312K sold.

Aperio Group first reported a position in ANIP in Q3 2016 and held it in 12 quarters. The position peaked at $577K in Q2 2019. 134 funds tracked by Wall St. Rank hold ANIP as of Q2 2020.

  • Aperio Group reported no remaining ANI Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Aperio Group sold 7,659 ANI Pharmaceuticals shares in Q2 2020, an estimated $312K.
  • Aperio Group first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 12 quarters.
  • Aperio Group's ANI Pharmaceuticals position peaked at $577K in Q2 2019.
  • 134 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2020.

Based on Aperio Group's 13F filing for Q2 2020, filed 13 Aug 2020.